OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer
17 Maggio 2021 - 07:30AM
OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer
Patrik De Haes
M.D. becomes
Non-executive Chairman
Leuven, BE
and Boston, MA, US
– May
17,
2021 –
7:30 AM CET – Oxurion NV
(Euronext Brussels: OXUR), a biopharmaceutical company developing
next generation standard of care ophthalmic therapies, with a
clinical stage portfolio in retinal vascular disorders, announces
in a planned succession, the promotion of Tom Graney, CFA from
Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of
the company. He takes over from Dr. Patrik De Haes, who after 14
years as CEO, has decided to move away from day-to-day management
of the company to become the Non-executive Chairman of Oxurion.
Thomas Clay, the outgoing Chairman of Oxurion, will remain on the
Board as a Non-executive Director of the company.
Mr. Graney has extensive capital markets and
business development experience in biotech as the CFO of several
successful public companies. This includes having raised >$500M
in capital for highly innovative companies like Oxurion and
completing a number of value creating business development
transactions. Tom also has an impressive track record of developing
high performing teams and talent everywhere he has worked both in
the United States and Europe.
Tom’s transatlantic experience in creating
significant company and shareholder value makes him uniquely
qualified to lead Oxurion as its next CEO as it moves its highly
differentiated assets through clinical development.
Tom joined Oxurion as CFO in October 2020, and
has over 25 years’ experience in senior finance, strategy, business
development and operational roles including most recently as CFO of
Generation Bio (NASDAQ: GBIO), and before that CFO of Vertex
Pharmaceuticals (NASDAQ: VRTX), and CFO and Head of Corporate
Strategy at Ironwood Pharmaceuticals (NASDAQ: IRWD). Earlier in his
career he spent 20 years with Johnson and Johnson, including CFO
roles at Ethicon, Tibotec and Janssen. Tom also serves on the board
of AC Immune (NASDAQ: ACIU).
Tom has an MBA in finance, marketing and
international business from the Leonard N. Stern School of Business
at New York University and a BS in accounting from the University
of Delaware. He is also a CFA charterholder.
Tom Graney, the incoming CEO of
Oxurion, said, “I am very excited and honored to become
the CEO of Oxurion as we build out our plan to create an important
ophthalmic company grounded in exceptional science. I am confident
that with THR-149 and THR-687, two highly promising and
differentiated new drug candidates, coupled with our extremely
talented team, Oxurion has the potential to successfully address a
broad range of retinal vascular disorders. This would allow us to
generate significant value for patients, payors and shareholders as
we look to disrupt and grow the $12 billion market for retinal
vascular disorders.”
Patrik De Haes M.D., the
incoming Chairman of Oxurion,
said, “I am looking forward to supporting Tom and the rest of the
Oxurion team in my new role as Chairman as we deliver a number of
important clinical development milestones in the months ahead. I am
confident that our drug candidates that have the potential to make
a significant difference to the lives of the large number of
patients with sight threatening disease, who require better
treatment options.”
Thomas Clay,
outgoing Chairman of
Oxurion, commented, “I would like to
thank Patrik for his high level of commitment and leadership to
Oxurion over the past 14 years and his desire to continue as
Chairman of the company. Oxurion is well placed for future success
given its industry-leading pipeline of next generation standard of
care ophthalmic therapies and a highly experienced team. I look
forward to working with Tom, Patrik and the rest of the board as a
Non-executive Director of Oxurion as we look to realize a
significant opportunity to bring value to patients and shareholders
as we progress the clinical development of THR-149 and THR-687 in
diabetic macular edema and other important retinal vascular
disorders.”
END
For further information please
contact:
Oxurion NVWouter Piepers, Global Head of Investor Relations&
Corporate CommunicationsTel: +32 478 33 56
32wouter.piepers@oxurion.com |
EU Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/Frazer
HallTel: +44 20 7638
9571oxurion@citigatedewerogerson.com USWestwicke, an ICR
CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to better preserve
vision in patients with retinal vascular disorders including
diabetic macular edema (DME), the leading cause of vision loss in
diabetic patients worldwide as well as other conditions, including
wet age-related macular degeneration (AMD) and retinal vein
occlusion (RVO).
Oxurion is aiming to build the leading global franchise in the
treatment of retinal vascular disorders based on the successful
development of its two novel therapeutics:
- THR-149, a plasma kallikrein
inhibitor being developed as a potential new standard of care for
the 40% of DME patients who respond suboptimally to anti-VEGF
therapy. THR-149 has shown positive topline Phase 1 results for the
treatment of DME. The company is currently conducting a Phase 2
clinical trial evaluating multiple injections of THR-149 in DME
patients who previously responded suboptimally to anti-VEGF
therapy.
- THR-687 is a pan-RGD integrin
antagonist that is initially being developed as a potential first
line therapy for DME patients. Positive topline results in a Phase
1 clinical study assessing THR-687 as a treatment for DME were
announced in 2020. THR-687 is expected to enter a Phase 2 clinical
trial in mid-2021. THR-687, also has the potential to deliver
improved treatment outcomes for patients with wet AMD and RVO.
Oxurion is headquartered in Leuven, Belgium, and
is listed on the Euronext Brussels exchange under the symbol OXUR.
More information is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mar 2023 a Mar 2024